High-throughput RNA sequencing transcriptome analysis of ABC-DLBCL reveals several tumor evasion strategies
Issued Date
2022-01-01
Resource Type
ISSN
10428194
eISSN
10292403
Scopus ID
2-s2.0-85129181345
Pubmed ID
35379068
Journal Title
Leukemia and Lymphoma
Volume
63
Issue
8
Start Page
1861
End Page
1870
Rights Holder(s)
SCOPUS
Bibliographic Citation
Leukemia and Lymphoma Vol.63 No.8 (2022) , 1861-1870
Suggested Citation
Serrano López J., Jiménez-Jiménez C., Chutipongtanate S., Serrano J., Rodríguez-Moreno M., Jiménez Á., Jiménez Y., G. Pedrero S., Laínez D., Alonso-Domínguez J.M., Llamas Sillero P., Piris M.Á., Sánchez-García J. High-throughput RNA sequencing transcriptome analysis of ABC-DLBCL reveals several tumor evasion strategies. Leukemia and Lymphoma Vol.63 No.8 (2022) , 1861-1870. 1870. doi:10.1080/10428194.2022.2056173 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/83913
Title
High-throughput RNA sequencing transcriptome analysis of ABC-DLBCL reveals several tumor evasion strategies
Author's Affiliation
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Ramathibodi Hospital
Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina
Hospital Universitario Reina Sofia
Universidad Complutense de Madrid
Hospital Universitario Fundación Jiménez Díaz
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Fundación Jiménez Díaz
Ramathibodi Hospital
Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina
Hospital Universitario Reina Sofia
Universidad Complutense de Madrid
Hospital Universitario Fundación Jiménez Díaz
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Fundación Jiménez Díaz
Other Contributor(s)
Abstract
Activated B-cell (ABC) lymphoma, a distinct molecular entity within diffuse large B-cell lymphoma (DLBCL), remains highly incurable, showing a worse response to standard immunochemotherapy. The discouraging results obtained in several clinical trials using proteasome inhibitors, tyrosine kinase inhibitors, or immunomodulators, lead to an intense search for new, potentially druggable biomarkers in DLBCL. In this study, we designed an experimental strategy for DLBCL to discover high- and low-abundance RNA-seq-derived transcripts involved in the oncogenic phenotype in patients diagnosed with ABC-DLBCL. Based on the results of a comparative analysis, 79 DE genes and two enriched gene sets related to metabolism and immunity were selected. Genes related to drug resistance, anti-inflammatory response, and tumor-cell dissemination were found to be up-regulated, while tumor suppressor genes were down-regulated. Then, we searched for the perturbagens most suitable for gene expression profiling (GEP) by iLINCS-CMap. Herein, we present a novel experimental approach that connects the omics signature of DLBCL with potential drugs for more accurate treatments.